Onkure Therapeutics, Inc. (OKUR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Onkure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines targeting specific cancer mutations, primarily through its lead candidate OKI-219, a selective PI3Kα inhibitor. The company operates as a single segment (clinical research) and is currently in the Phase 1a/1b clinical trial stage for OKI-219. The financial statements reflect the combined entity following the October 2024 reverse recapitalization merger with Reneo Pharmaceuticals, Inc.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(15.4) million | $(14.1) million | $(31.3) million | $(23.7) million |
| Operating Expenses | $16.3 million | $14.3 million | $33.3 million | $24.2 million |
| Research & Development (R&D) | $12.6 million | $10.8 million | $25.6 million | $19.3 million |
| General & Administrative (G&A) | $3.7 million | $3.6 million | $7.7 million | $4.9 million |
| Interest Income | $0.9 million | $0.2 million | $2.0 million | $0.5 million |
| Cash and Cash Equivalents (End of Period) | $83.4 million (as of June 30, 2025) | |||
| Accumulated Deficit | $(186.0) million (as of June 30, 2025) | |||
| Net Cash Used in Operating Activities | N/A | $(27.3) million | $(17.1) million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by $9.1 million (38%) for the six months ended June 30, 2025, compared to the same period in 2024. This was driven by a $6.3 million increase in R&D and a $2.8 million increase in G&A.
- R&D Drivers: The increase in R&D expenses was primarily due to higher clinical trial and outsourced manufacturing costs ($3.1 million increase) and increased personnel-related costs, including share-based compensation ($1.9 million increase).
- G&A Drivers: The rise in G&A expenses was attributed to increased personnel costs ($2.9 million), including share-based compensation ($2.2 million), and higher professional fees. These were partially offset by a $1.3 million decrease in legal expenses related to the 2024 Merger.
- Interest Income: Interest income increased significantly ($1.5 million YTD) due to higher cash balances available for investment following the Merger and Concurrent Financing.
- Cash Position: Cash and cash equivalents decreased by $27.4 million during the first six months of 2025, primarily due to operating losses and changes in working capital.
Guidance, Outlook, and Risks
- Liquidity and Runway: Management believes current cash resources ($83.4 million) are sufficient to fund operations for at least the next 12 months from the date of issuance. The company expects to continue incurring significant losses as it advances clinical trials.
- Clinical Progress: OKI-219 is in a Phase 1a/1b trial (PIKture-01). Preliminary safety and PK data were announced in December 2024, supporting the initiation of Part 1b. Additional data is expected in Q4 2025.
- Capital Needs: The company will require substantial additional capital to complete development and commercialization. Future funding may come from equity or debt financings, which could result in dilution, or strategic collaborations.
- Legal Proceedings: Two shareholder complaints were filed in September 2024 regarding the Merger and Concurrent Financing, alleging misrepresentations in the Proxy Statement/Prospectus. The company intends to vigorously defend against these claims.
- Regulatory and Market Risks: Risks include the unpredictability of clinical trial outcomes, regulatory approval processes (FDA/EMA), potential delays in patient enrollment, and reliance on third-party manufacturers (single-source suppliers for drug substance and product).
Key Facts for Investor Verification
- Cash Burn Rate: Verify the sustainability of the $27.3 million cash burn over six months against the $83.4 million cash balance to confirm the 12-month runway estimate.
- Clinical Trial Status: Monitor the upcoming Q4 2025 data release for the PIKture-01 trial, as negative results could materially impact the stock price and future funding.
- Legal Exposure: Track the status of the pending shareholder lawsuits (Thomas v. Reneo and Kent v. Reneo) regarding the Merger, as outcomes could involve significant costs or delays.
- Supply Chain Concentration: Confirm the status of relationships with single-source suppliers (PharmaBlock Sciences for drug substance; STA Pharmaceutical for drug product) and any progress on diversification.
- Share-Based Compensation: Note the significant increase in share-based compensation ($5.7 million YTD 2025 vs. $1.9 million YTD 2024), which impacts net loss and future dilution.